News
ENLV
1.400
-5.41%
-0.080
BRIEF-Enlivex Announces Authorization From The Danish Regulatory Agency For Its Randomized, Controlled Phase I/II Trial
Enlivex Announces Authorization From The Danish Regulatory Agency For Its Randomized, Controlled Phase I/II Trial. The company says it has received authorization from the agency for the trial. The trial is evaluating allocetra in patients with KNEE OSTEOARTHRITIS.
Reuters · 2d ago
Enlivex Advances Osteoarthritis Trial in Denmark
TipRanks · 2d ago
ENLIVEX ANNOUNCES AUTHORIZATION FROM THE DANISH REGULATORY AGENCY FOR THE COMPANY’S RANDOMIZED, CONTROLLED PHASE I/II TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH KNEE OSTEOARTHRITIS
Reuters · 2d ago
Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why
NASDAQ · 3d ago
BSGM, ENLV and WISA among mid-day movers
U.S. Economy BSGM, ENLV and WISA among mid-day movers in SA. Kaival Brands Innovations Group is one of the biggest gainers. Marinus Pharmaceuticals is among the biggest losers in the biotech sector. South Africa's economy is expected to grow by 0.7% in the first quarter.
Seeking Alpha · 3d ago
Weekly Report: what happened at ENLV last week (0408-0412)?
Weekly Report · 3d ago
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
Citigroup cut the price target for Starbucks Corporation from $102 to $95. Morgan Stanley raised Netflix's price target from $600 to $700. The price target was slashed for Tesla, Inc. (NASDAQ:TSLA) Fastenal Company shares fell 6.5% on Thursday.
Benzinga · 6d ago
Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Enlivex Therapeutics Price Target Cut to $7.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Lowers Price Target to $7
Benzinga · 6d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
TipRanks · 6d ago
ENLIVEX THERAPEUTICS LTD <ENLV.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $12
Reuters · 6d ago
Health Care Sector Update for 04/11/2024: ENLV, RLYB, JNJ, UNH, ELYM
NASDAQ · 04/11 20:00
Nasdaq Jumps 250 Points; Crude Oil Down 1%
U.S. Stocks traded higher toward the end of trading on Thursday. The Nasdaq Composite surged more than 250 points. The Dow traded up 0.18% while the NASDAQ rose 1.63%. Information technology shares rose by 2.2% and energy shares fell by 0.3%. Constellation Brands reported better-than-expected fourth-quarter earnings.
Benzinga · 04/11 19:21
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 04/11 17:33
NKTR, VERU and EGIO among mid-day movers
U.S. Economy NKTR, VERU and EGIO among mid-day movers. Rent the Runway (RENT) and Rallybio Corp are among the gainers. Aptevo Therapeutics (NA) is one of the biggest losers.
Seeking Alpha · 04/11 16:55
BUZZ-U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
The benchmark S&P 500 and the Nasdaq gained on Thursday. Producer prices data soothed investor jitters about sticky inflation. The Dow Jones Industrial Average was down 0.36% in the morning. Constellation Brands, Nike, Rocket Lab and Domino's Pizza are among the stocks on the move.
Reuters · 04/11 16:07
Dow Dips 100 Points; CarMax Earnings Miss Views
U.S. Stocks traded mixed midway through trading on Thursday. The Dow Jones index fell around 100 points and the NASDAQ rose 0.50%. Information technology shares rose by 0.1% while financial shares fell by 1.3%. CarMax reported weaker-than-expected fourth-quarter earnings. Rallybio Corporation shares shot up 73% after announcement of collaboration with Johnson & Johnson.
Benzinga · 04/11 15:55
Enlivex stock plunges 50% on mixed results from sepsis study
Enlivex Therapeutics stock plunges 50% on mixed results from sepsis study. The company reported bias issues in a Phase 2 study of its cell therapy product Allocetra in the treatment of sepsi. The study evaluated the product in patients with community-acquired pneumonia and other infections.
Seeking Alpha · 04/11 14:56
Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers
Healthcare On the Move Enlivex Therapeutics, Nyxoah SA, China SXT Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.07% to 1650.74. Rallybio and Alpine Immune Sciences among healthcare gainers.
Seeking Alpha · 04/11 14:04
More
Webull provides a variety of real-time ENLV stock news. You can receive the latest news about Enlivex Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ENLV
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.